October 8, 2019

The Honorable James R. Langevin
House of Representatives
Washington, DC 20515

Dear Congressman Langevin:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
October 8, 2019

The Honorable David P. Joyce
House of Representatives
Washington, DC 20515

Dear Congressman Joyce:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

[Signature]

Steve Dickson
Administrator
October 8, 2019

The Honorable Don Bacon
House of Representatives
Washington, DC 20515

Dear Congressman Bacon:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

[Signature]

Steve Dickson
Administrator
October 8, 2019

The Honorable Susan Wild
House of Representatives
Washington, DC 20515

Dear Congresswoman Wild:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
Dear Congressman Khanna:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
Dear Congressman Carson:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
October 8, 2019

The Honorable Brian Fitzpatrick
House of Representatives
Washington, DC 20515

Dear Congressman Fitzpatrick:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
October 8, 2019

The Honorable David McKinley, PE
House of Representatives
Washington, DC 20515

Dear Congressman McKinley:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
October 8, 2019

The Honorable Gwen Moore
House of Representatives
Washington, DC 20515

Dear Congressman Moore:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

Steve Dickson
Administrator
October 8, 2019

The Honorable Sheila Jackson Lee
House of Representatives
Washington, DC 20515

Dear Congressman Lee:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
If I can be of further assistance, please contact me or Philip Newman, Assistant Administrator for Government and Industry Affairs, at (202) 267-3277.

Sincerely,

[Signature]

Steve Dickson
Administrator
October 8, 2019

The Honorable Eleanor Holmes Norton
House of Representatives
Washington, DC 20515

Dear Congresswoman Norton:

Thank you for your August 19 letter, cosigned by your congressional colleagues, urging the Federal Aviation Administration (FAA) to implement regulations to require all certificate holders operating passenger aircraft to carry an opioid antagonist – naloxone – in emergency medical kits. We appreciate and share your concerns.

Per Section 307 of the FAA Reauthorization Act of 2018 (P.L 115-254), and as mentioned in your letter, the FAA is evaluating potential modifications to the emergency medical equipment requirements – including the contents of first-aid kits – under part 121 of Title 14 of the Code of Federal Regulations. In conjunction with that evaluation, the FAA asked the Aerospace Medical Association (AsMA) to conduct a study of the required emergency medical kit contents for commercial aircraft operating under part 121. The FAA received the AsMA report in June 2019. In late August 2019, the FAA’s Office of Aerospace Medicine completed its review of the study and concurred with AsMA’s recommendation regarding the need to update emergency medical kits to include opioid antagonists.

The FAA is currently reviewing the best way for part 121 air carriers to include opioid antagonists as part of the emergency medical kits carried aboard their fleets. The agency is considering the revision of current regulatory requirements but recognizes that rulemaking takes time due to the notice and comment requirements of the Administrative Procedure Act. As with any other rulemaking, the FAA would have to consider the benefits and costs of the proposed changes. For example, the FAA would have to evaluate, amongst others, the impact of the regulatory changes on part 121 air carriers that would have to procure new emergency medical kits for their aircraft fleets, dispose or update the old kits, and provide crewmember training and familiarization with the new kits.

The FAA is also considering other means to convey valuable information and recommended actions for part 121 air carriers. Since air carriers may voluntarily carry additional medications in their aircraft emergency medical kits, the FAA will seek to encourage the expeditious and voluntary inclusion of opioid antagonists in the kits prior to the effective date of a final rule.

We have sent an identical letter to each of the cosigners of your letter.
<table>
<thead>
<tr>
<th>Name</th>
<th>Office Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUSAN WILD</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 1607 LONGWORTH HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>DAVID B. MCKINLEY, PE</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 2239 RAYBURN HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>DAVID P. JOYCE</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 1124 LONGWORTH HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>DON BACON</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 1024 LONGWORTH HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>ANDRE CARSON</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 2135 RAYBURN HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>SHEILA JACKSON LEE</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 2079 RAYBURN HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>RO KHANNA</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 221 Cannon HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>GWEN MOORE</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 2252 RAYBURN HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>ELEANOR HOLMES NORTON</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 2136 RAYBURN HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
<tr>
<td>BRIAN FITZPATRICK</td>
<td>UNITED STATES HOUSE OF REPRESENTATIVES 1722 LONGWORTH HOB WASHINGTON, DC 20515</td>
<td>(202) 225-3211</td>
</tr>
</tbody>
</table>